In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Homology Medicines (FIXX), with a price target of $30.00. The company’s shares closed last Friday at $6.51, close to its 52-week low of $6.08.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 64.9% and a 63.3% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Homology Medicines with a $26.60 average price target, a 308.6% upside from current levels. In a report issued on May 3, BTIG also maintained a Buy rating on the stock with a $35.00 price target.
Based on Homology Medicines’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $980K and GAAP net loss of $29.79 million. In comparison, last year the company earned revenue of $563K and had a GAAP net loss of $24.17 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FIXX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.